Real-world study shows greater reductions in HbA1c and body weight for patients with proportion of days covered \u226560 percent<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 4, 2023 (HealthDay News) — Use of once-weekly subcutaneous semaglutide is associated with sustained reductions in hemoglobin A1c (HbA1c) and body weight, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Oct. 2 to 6 in Hamburg, Germany.<\/p>\n
Cheli Melzer-Cohen, from Maccabi Health Services in Tel Aviv, Israel, and colleagues examined the effect of subcutaneous semaglutide on HbA1c and weight reduction in a large cohort of adult patients treated for up to three years. Data were included for 23,442 patients (mean age, 62.2 years; mean weight, 94.1 kg; mean body mass index, 33.7 kg\/m2<\/sup>; <\/sup>mean HbA1c, 7.6 percent). <\/sup><\/p>\n The researchers found that among 75 percent of patients, the proportion of days covered (PDC) within the first six months was more than 60 percent. In the intent-to-treat analysis, there were significant reductions in HbA1c (by 0.77 percent to a mean of 6.82 percent) and in body weight (by 4.7 kg to a mean of 89.7 kg). The decreases in HbA1c and weight were more pronounced for glucagon-like peptide-1 receptor agonist (GLP-1-RA)-naive patients than those who had previously received GLP-1-RA (HbA1c, \u00e2\u0088\u00920.87 versus \u00e2\u0088\u00920.54 percent; weight, \u00e2\u0088\u00925.51 versus \u00e2\u0088\u00923.01 kg). Patients with PDC \u00e2\u0089\u00a560 versus <60 percent had greater reductions in both HbA1c and weight. In the intent-to-treat analysis, reductions in both HbA1c and weight were maintained over three years. In the as-treated analysis, the durable pattern of reduction was more evident.<\/p>\n “In this large real-world study, we were able to show durable reductions in HbA1c and body weight with emphasis on drug adherence,” coauthor Avraham Karasik, M.D., also from Maccabi Health Services, said in a statement. “Data are in line with results in randomized controlled trials and show the long-term stable benefit of once-weekly semaglutide.”<\/strong><\/p>\n The study was funded by Novo Nordisk, the manufacturer of semaglutide.<\/p>\n Abstract<\/a><\/p>\n